Telix Breaks Records with 28 Presentations at EANM 2025

Telix Pharmaceuticals Limited has announced an impressive presence at the upcoming 38th Annual Congress of the European Association of Nuclear Medicine (EANM), set to take place in Barcelona from October 4 to 8, 2025. The company will present a record-breaking total of 28 company-related abstracts, showcasing its advancements in nuclear medicine and MedTech.

Dr. David N. Cade, the Group Chief Medical Officer at Telix, expressed enthusiasm about the event, stating, “We are pleased to showcase our late-stage and next generation development programs and innovations in MedTech at EANM – the largest gathering of nuclear medicine professionals worldwide.” Among the highlights are data from the Phase 3 ProstACT Global trial involving TLX591 for metastatic castration-resistant prostate cancer (mCRPC), as well as therapeutic trials of TLX101 in glioma and real-world experience with TLX250-CDx for clear cell renal cell carcinoma (ccRCC).

In addition to presentations, Telix will host a sponsored symposium focusing on case studies related to CAIX and FAP targeting theranostics. This symposium aims to address critical innovations in oncology drug development and radiopharmaceutical therapy. The event will take place on October 5, 2025, from 13:15 to 14:45 CEST in Room 116, CCI Barcelona, chaired by A. Italiano from Institut Bergonié in France.

A variety of oral presentations are also scheduled, each emphasizing significant advancements in the understanding and treatment of various cancers. For example, on October 6, 2025, L. Papp from the Medical University of Vienna will present findings on a novel alternative to transfer learning for evaluating prostate cancer cohorts. This presentation is part of a broader agenda that includes studies on tumor-stroma dynamics, immunotherapy, and the latest techniques in deep learning for tumor classification.

Telix will also support the EANM Sanjiv Sam Gambhir Young Investigator Award, honoring the memory of a distinguished figure in the field of nuclear medicine. Attendees are invited to visit booth #78 to learn more about Telix’s commercial offerings, including Illuccix®, the company’s PSMA-PET imaging agent, and its innovative theranostic pipeline featuring the SENSEI® miniature drop-in gamma probe and QDOSE® dosimetry software.

The significance of Telix’s participation in EANM extends beyond mere presentations. With the company’s commitment to enhancing global access to cancer imaging and therapy, as demonstrated through its wholly-owned subsidiary, Rhine Pharma, Telix is poised to make a considerable impact on the nuclear medicine community.

Further details about Telix and its ongoing projects can be found on their official website, where they provide updates on recent developments and industry-related news. As Telix Pharmaceuticals continues to expand its portfolio, the outcomes of its presentations at EANM 2025 could play a crucial role in shaping future cancer treatments and patient care.